Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent

Transforming the Experience of Chemotherapy for Patients

What's New at Aileron

Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.

ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.

Latest News